Pec Infiltration With Liposomal Bupivacaine for Breast Surgery

• Status: Recruiting
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to compare pain control after breast surgery using either liposomal bupivacaine or bupivacaine when infiltrated during an ultrasound guided pectoralis 1 and 2 block. Both medications, liposomal bupivacaine and bupivacaine, are standard of care in these types of surgeries.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Minnesota; University of Minnesota - Clinical and Translational Science Institute
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• • All patients undergoing partial mastectomy procedures.

• Ages 18-75

Exclusion Criteria:

• • Patient on chronic anticoagulation

• Pregnant women

• Non-english speaking patients

• Any individuals who are unable to give informed consent

• Any individual with diminished capacity to give informed consent

• Allergy to local anesthetics

• Patients who remain intubated overnight after surgery or who are unable to provide information regarding their pain immediately postoperatively

• Daily use of opioid for more than three weeks

• Significant liver disease, defined as liver enzymes greater than 3x the upper limit of normal

• Lack of patient cooperation including those patients who refuse a MAC anesthetic

• Contraindication to regional anesthesia

• Infection at injection site

• Inability to guarantee sterile equipment or sterile conditions for the block

• Patient refusal

• Severe Coagulopathy or bleeding disorder